









Markets
/
Stocks
/
nasdaq-rlay
/

Relay Therapeutics Inc

RLAY

8.920USD

+0.770+9.45%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.54BMarket Cap

LossP/E TTM



Relay Therapeutics Inc

8.920

+0.770+9.45%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Relay Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Relay Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 13 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 14.55.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Relay Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

13 / 392

Overall Ranking

99 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Relay Therapeutics Inc Highlights

StrengthsRisks

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 624.62% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.01M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.01M.

Undervalued

The company’s latest PE is -5.20, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 170.34M shares, decreasing 20.08% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 285.09K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.27.

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

14.545

Target Price

+71.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Relay Therapeutics Inc is 7.25, ranking 135 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.27

Change

-0.02



Financials

8.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.86

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.58

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Relay Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Relay Therapeutics Inc is 6.83, ranking 216 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.20, which is -82.49% below the recent high of -0.91 and -69.18% above the recent low of -8.79.

Score

Industry at a Glance

Previous score

6.83

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 13/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Relay Therapeutics Inc is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 14.50, with a high of 19.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

9.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Strong Buy

Current Rating

14.545

Target Price

+71.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Relay Therapeutics Inc

RLAY

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Relay Therapeutics Inc is 9.16, ranking 34 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.62 and the support level at 7.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.26

Change

1.9

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.213

Buy

RSI(14)

61.004

Neutral

STOCH(KDJ)(9,3,3)

76.528

Buy

ATR(14)

0.654

High Vlolatility

CCI(14)

136.408

Buy

Williams %R

4.500

Overbought

TRIX(12,20)

0.090

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

8.476

Buy

MA10

8.149

Buy

MA20

7.912

Buy

MA50

8.011

Buy

MA100

7.062

Buy

MA200

5.236

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Relay Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 98.28%, representing a quarter-over-quarter increase of 1.20%. The largest institutional shareholder is Steven Cohen, holding a total of 14.77M shares, representing 8.52% of shares outstanding, with 34.97% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

SB Investment Advisers (UK) Limited

27.90M

Commodore Capital LP

17.00M

+27.34%

Point72 Asset Management, L.P.

Star Investors

14.77M

+9.88%

Casdin Capital, LLC

11.34M

-0.50%

BlackRock Institutional Trust Company, N.A.

10.48M

-1.35%

The Vanguard Group, Inc.

Star Investors

9.37M

+0.17%

Bellevue Asset Management AG

8.35M

+1.39%

Tang Capital Management, LLC

8.07M

State Street Investment Management (US)

5.07M

-2.63%

Nextech Invest, Ltd.

3.85M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Relay Therapeutics Inc is 4.64, ranking 74 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.61. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.